Tissue sampling results were compared to final diagnoses, based on the following in decreasing priority: surgical findings/pathology, EUS or ERCP sampling www.selleckchem.com/products/pifithrin-alpha.html when malignant, and long-term clinical follow-up. Results: Of the 77 patients providing study consent, 26 were excluded due to: (a) ERCP not performed after EUS-FNA provided onsite diagnosis, mass appeared resectable, and referred for expedited surgery (n = 14), (b) biliary stricture not present on ERCP (stones or other cause of jaundice) (n = 8), (c)

EUS-FNA provided diagnosis in patient with patent biliary stent (n = 1), (d) ERCP not performed after EUS revealed no obstruction (suspected hepatic etiology) (n = 3). Final diagnoses in the remaining 51 patients were: pancreatic cancer (n = 34), bile duct cancer

(n = 14), and inflammatory stricture or chronic pancreatitis (n = 3). Diagnoses were based ACP-196 manufacturer on surgery (n = 13), malignancy on EUS or ERCP sampling (n = 37), and long-term follow-up (n = 1). EUS-FNA was superior to ERCP sampling overall and for pancreatic masses (Table), and similar to ERCP for biliary masses and indeterminate strictures (defined as obstructive jaundice without visible mass on pre-procedure CT / MRI). EUS-FNA yielded malignant diagnoses without complications in all cholangiocarcinoma patients with positive ERCP tissue sampling results, although two were from FNA of distant sites (lymph node, liver Gefitinib mw lesion). Conclusion: EUS-FNA is superior to ERCP sampling for establishing diagnoses in suspected malignant biliary obstruction, and particularly for pancreatic masses. EUS-FNA appears equivalent to ERCP for tissue diagnoses in patients with biliary tumors and indeterminate strictures. Given the overall superior performance characteristics of EUS-FNA, we believe EUS should be performed prior to ERCP in all patients with suspected malignant biliary obstruction. Combining

EUS / ERCP at one session may maximize diagnostic and therapeutic benefits.   Sensitivity Accuracy EUS-FNA ERCP p-value EUS-FNA ERCP p-value OVERALL (n = 51) 94% 50% 0.0001 94% 53% 0.0001 Pancreatic mass (n = 36) 100% 38% 0.0001 100% 42% 0.0001 Biliary mass or stricture < n = 15) 79% 79% NS 80% 80% NS Indeterminate stricture (n = 15) 80% 67% NS 80% 67% NS "
“Defects in natural killer (NK) cell functions are necessary for tumor immune escape, but their underlying regulatory mechanisms in human cancers remain largely unknown. Here we show, in detailed studies of NK cells in 294 untreated patients with hepatocellular carcinoma (HCC), that accumulation of functional NK cells in HCC tissues could predict improved survival of patients. However, in patients with advanced-stage HCC, NK cells were significantly decreased in number with impaired tumor necrosis factor alpha (TNF-α) and interferon-gamma (IFN-γ) production.